Biogen BIIB reported second-quarter earnings of $9.15 per share, which beat the analyst consensus estimate of $7.53 by 21.51%. This is a 57.76% increase over earnings of $5.8 per share from the same period last year.
The company reported quarterly sales of $3.617 billion, which beat the analyst consensus estimate of $3.48 billion by 3.94%. This is a 7.75% increase over sales of $3.357 billion the same period last year.
Biogen also raised 2019 guidance from $28-$29 to $31.50-$32.30 versus a $29.70 estimate.
Biogen shares were trading up 1.59% at $236.17 in Tuesday’s pre-market session. The stock has a 52-week high of $388.67 and a 52-week low of $216.12.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
